PremiumRatingsTandem Diabetes Care: Strong Performance, Promising Outlook, and Buy Rating Affirmed by William Plovanic Tandem Diabetes price target lowered to $30 from $36 at Piper Sandler Tandem Diabetes price target lowered to $20 from $22 at Wells Fargo PremiumThe FlyTandem Diabetes reports Q1 adjusted EBITDA ($4.7M) vs. ($14.4M) Tandem Diabetes sees FY25 revenue $997M-$1.007B, consensus $999M TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlyTandem Diabetes launches new Control-IQ+ technology Positive Outlook for Tandem Diabetes Care: Buy Rating Affirmed Amid Upcoming Trial Results Optimistic Buy Rating for Tandem Diabetes Care Amid Attractive Valuation and Growth Potential 
